234 related articles for article (PubMed ID: 36329288)
21. Characterization of Diffuse Gliomas With Histone H3-G34 Mutation by MRI and Dynamic 18F-FET PET.
Vettermann FJ; Felsberg J; Reifenberger G; Hasselblatt M; Forbrig R; Berding G; la Fougère C; Galldiks N; Schittenhelm J; Weis J; Albert NL; Schüller U
Clin Nucl Med; 2018 Dec; 43(12):895-898. PubMed ID: 30358620
[TBL] [Abstract][Full Text] [Related]
22. Exploring the mechanism of 18F-fluorodopa uptake in recurrent high-grade gliomas: A comprehensive histomolecular-positron emission tomography analysis.
Cobes N; Tran S; Mathon B; Nichelli L; Bielle F; Touat M; Kas A; Rozenblum L
Eur J Neurol; 2024 Jan; 31(1):e16093. PubMed ID: 37823694
[TBL] [Abstract][Full Text] [Related]
23. Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[
Bauer EK; Stoffels G; Blau T; Reifenberger G; Felsberg J; Werner JM; Lohmann P; Rosen J; Ceccon G; Tscherpel C; Rapp M; Sabel M; Filss CP; Shah NJ; Neumaier B; Fink GR; Langen KJ; Galldiks N
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1486-1495. PubMed ID: 32034446
[TBL] [Abstract][Full Text] [Related]
24.
Patel CB; Fazzari E; Chakhoyan A; Yao J; Raymond C; Nguyen H; Manoukian J; Nguyen N; Pope W; Cloughesy TF; Nghiemphu PL; Czernin J; Lai A; Ellingson BM
J Neurooncol; 2018 Sep; 139(2):399-409. PubMed ID: 29679199
[TBL] [Abstract][Full Text] [Related]
25. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
[TBL] [Abstract][Full Text] [Related]
26. 18F-fluoro-ethyl-tyrosine positron emission tomography for grading and estimation of prognosis in patients with intracranial gliomas.
Gempt J; Bette S; Ryang YM; Buchmann N; Peschke P; Pyka T; Wester HJ; Förster S; Meyer B; Ringel F
Eur J Radiol; 2015 May; 84(5):955-62. PubMed ID: 25748815
[TBL] [Abstract][Full Text] [Related]
27. Maximum Uptake and Hypermetabolic Volume of 18F-FDOPA PET Estimate Molecular Status and Overall Survival in Low-Grade Gliomas: A PET and MRI Study.
Tatekawa H; Yao J; Oughourlian TC; Hagiwara A; Wang C; Raymond C; Lai A; Cloughesy TF; Nghiemphu PL; Liau LM; Salamon N; Ellingson BM
Clin Nucl Med; 2020 Dec; 45(12):e505-e511. PubMed ID: 33031233
[TBL] [Abstract][Full Text] [Related]
28. Detection of recurrent high-grade glioma using microstructure characteristics of distinct metabolic compartments in a multimodal and integrative 18F-FET PET/fast-DKI approach.
Lohmeier J; Radbruch H; Brenner W; Hamm B; Hansen B; Tietze A; Makowski MR
Eur Radiol; 2024 Apr; 34(4):2487-2499. PubMed ID: 37672058
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement.
Rosen J; Stoffels G; Lohmann P; Bauer EK; Werner JM; Wollring M; Rapp M; Felsberg J; Kocher M; Fink GR; Langen KJ; Galldiks N
Sci Rep; 2021 Oct; 11(1):20828. PubMed ID: 34675225
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of 3'-deoxy-3'-18F-fluorothymidine ([(18)F] FLT PET) in patients with recurrent malignant gliomas.
Zhao F; Cui Y; Li M; Fu Z; Chen Z; Kong L; Yang G; Yu J
Nucl Med Biol; 2014 Sep; 41(8):710-5. PubMed ID: 24929963
[TBL] [Abstract][Full Text] [Related]
31. The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers.
Skoblar Vidmar M; Doma A; Smrdel U; Zevnik K; Studen A
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743228
[TBL] [Abstract][Full Text] [Related]
32. Flutriciclamide (18F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein.
Fan Z; Calsolaro V; Atkinson RA; Femminella GD; Waldman A; Buckley C; Trigg W; Brooks DJ; Hinz R; Edison P
J Nucl Med; 2016 Nov; 57(11):1753-1759. PubMed ID: 27261523
[TBL] [Abstract][Full Text] [Related]
33. Comparison of O-(2-
Verger A; Filss CP; Lohmann P; Stoffels G; Sabel M; Wittsack HJ; Kops ER; Galldiks N; Fink GR; Shah NJ; Langen KJ
World Neurosurg; 2018 May; 113():e727-e737. PubMed ID: 29510293
[TBL] [Abstract][Full Text] [Related]
34. Combination of pre-treatment dynamic [
Li Z; Holzgreve A; Unterrainer LM; Ruf VC; Quach S; Bartos LM; Suchorska B; Niyazi M; Wenter V; Herms J; Bartenstein P; Tonn JC; Unterrainer M; Albert NL; Kaiser L
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):535-545. PubMed ID: 36227357
[TBL] [Abstract][Full Text] [Related]
35. IDH mutation is paradoxically associated with higher
Verger A; Metellus P; Sala Q; Colin C; Bialecki E; Taieb D; Chinot O; Figarella-Branger D; Guedj E
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1306-1311. PubMed ID: 28293705
[TBL] [Abstract][Full Text] [Related]
36. TSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma.
Pigeon H; Pérès EA; Truillet C; Jego B; Boumezbeur F; Caillé F; Zinnhardt B; Jacobs AH; Le Bihan D; Winkeler A
Neuro Oncol; 2019 Jun; 21(6):755-764. PubMed ID: 30721979
[TBL] [Abstract][Full Text] [Related]
37. Predictive IDH Genotyping Based on the Evaluation of Spatial Metabolic Heterogeneity by Compartmental Uptake Characteristics in Preoperative Glioma Using
Lohmeier J; Radbruch H; Brenner W; Hamm B; Tietze A; Makowski MR
J Nucl Med; 2023 Nov; 64(11):1683-1689. PubMed ID: 37652542
[TBL] [Abstract][Full Text] [Related]
38. Static and dynamic
Verger A; Stoffels G; Bauer EK; Lohmann P; Blau T; Fink GR; Neumaier B; Shah NJ; Langen KJ; Galldiks N
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):443-451. PubMed ID: 29043400
[TBL] [Abstract][Full Text] [Related]
39. Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study.
Verburg N; Koopman T; Yaqub MM; Hoekstra OS; Lammertsma AA; Barkhof F; Pouwels PJW; Reijneveld JC; Heimans JJ; Rozemuller AJM; Bruynzeel AME; Lagerwaard F; Vandertop WP; Boellaard R; Wesseling P; de Witt Hamer PC
Neuro Oncol; 2020 Mar; 22(3):412-422. PubMed ID: 31550353
[TBL] [Abstract][Full Text] [Related]
40. Enhancing predictability of IDH mutation status in glioma patients at initial diagnosis: a comparative analysis of radiomics from MRI, [
Kaiser L; Quach S; Zounek AJ; Wiestler B; Zatcepin A; Holzgreve A; Bollenbacher A; Bartos LM; Ruf VC; Böning G; Thon N; Herms J; Riemenschneider MJ; Stöcklein S; Brendel M; Rupprecht R; Tonn JC; Bartenstein P; von Baumgarten L; Ziegler S; Albert NL
Eur J Nucl Med Mol Imaging; 2024 Feb; ():. PubMed ID: 38396261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
